RXi Pharmaceuticals (NASDAQ:RXII) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Valuation & Earnings
This table compares RXi Pharmaceuticals and Kiniksa Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|RXi Pharmaceuticals||$10,000.00||149.80||-$12.45 million||($4.20)||-0.08|
|Kiniksa Pharmaceuticals||N/A||N/A||-$64.87 million||N/A||N/A|
This is a breakdown of current ratings and recommmendations for RXi Pharmaceuticals and Kiniksa Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
RXi Pharmaceuticals currently has a consensus target price of $3.00, suggesting a potential upside of 777.19%. Kiniksa Pharmaceuticals has a consensus target price of $34.67, suggesting a potential upside of 72.13%. Given RXi Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe RXi Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals.
This table compares RXi Pharmaceuticals and Kiniksa Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
9.6% of RXi Pharmaceuticals shares are held by institutional investors. Comparatively, 37.9% of Kiniksa Pharmaceuticals shares are held by institutional investors. 1.0% of RXi Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
RXi Pharmaceuticals Company Profile
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. RXi Pharmaceuticals Corporation has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.